drugset / Trial / NCT00922636

A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

NCT00922636

Phase 2/3 Completed 340 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of your child's participation in this study is to determine whether LY2216684 can help pediatric patients with attention-deficit/hyperactivity disorder (ADHD); and assess the safety of LY2216684 and any side effects that might be associated with it.

Timeline

Start
2009-06
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylphenidate Small molecule 18 mg Oral
Comparator Methylphenidate Small molecule 54 mg Oral
Subject edivoxetine Small molecule 0.1 mg/kg Oral
Subject edivoxetine Small molecule 0.2 mg/kg Oral
Subject edivoxetine Small molecule 0.3 mg/kg Oral